COLL - Collegium Pharmaceutical, Inc.
13.52 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 13.61 |
| Open | 13.58 |
| Bid | 13.15 x 900 |
| Ask | 14.38 x 1300 |
| Day's Range | 13.23 - 13.88 |
| 52 Week Range | 13.10 - 28.91 |
| Volume | 423,658 |
| Avg. Volume | 419,333 |
| Market Cap | 451.189M |
| Beta (3Y Monthly) | 0.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 |
| Earnings Date | Mar 7, 2018 - Mar 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.00 |
- GlobeNewswire•16 days ago
Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut, M.D., as the company’s first Chief Medical Officer, effective April 1, 2019. In this newly created role, Dr. Malamut will lead Collegium’s Clinical, Medical Affairs, Regulatory and Scientific Affairs functions. “We are excited to have Rick join the Collegium leadership team.
- GlobeNewswire•17 days ago
Collegium to Present at Upcoming Investor Conferences
STOUGHTON, Mass., April 01, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
- Simply Wall St.•18 days ago
Read This Before Buying Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip sid...
- Zacks•24 days ago
Collegium Pharmaceutical (COLL) Upgraded to Buy: What Does It Mean for the Stock?
Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Motley Fool•last monthAssertio Therapeutics, Inc (ASRT) Q4 2018 Earnings Conference Call Transcript
ASRT earnings call for the period ending December 31, 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of COLL earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Collegium Pharmaceutical Inc Earnings Call
Motley Fool•2 months agoCollegium Pharmaceutical Inc (COLL) Q4 2018 Earnings Conference Call Transcript
COLL earnings call for the period ending December 31, 2018.
- GlobeNewswire•2 months ago
Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
Xtampza® ER Prescriptions Grew 233% in 2018Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full YearCash and Cash Equivalents were.
- Zacks•2 months ago
Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•2 months ago
ASRT or COLL: Which Is the Better Value Stock Right Now?
ASRT vs. COLL: Which Stock Is the Better Value Option?
- GlobeNewswire•2 months ago
Collegium to Host Conference Call to Discuss Fourth Quarter 2018 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Feb. 13, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
- Simply Wall St.•2 months ago
Breakeven On The Horizon For Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL): Collegium Pharmaceutical, Inc.,Read More...
- Zacks•3 months ago
ASRT vs. COLL: Which Stock Should Value Investors Buy Now?
ASRT vs. COLL: Which Stock Is the Better Value Option?
- GlobeNewswire•3 months ago
Report: Developing Opportunities within Enterprise Products Partners, Antero Midstream Partners LP, Integrated Device Technology, Collegium Pharmaceutical, GAIN Capital, and United Technologies — Future Expectations, Projections Moving into 2019
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Collegium Provides Full-Year 2019 Financial Guidance
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management today provided full-year 2019 guidance for Xtampza ER revenues, Nucynta Franchise revenues, and total operating expenses. “With strong growth for Xtampza ER in 2018 and the addition of the Nucynta Franchise, Collegium built a solid foundation upon which to progress in the year ahead,” said Joe Ciaffoni, Chief Executive Officer. Xtampza ER revenue for 2019 is estimated to be between $95 million and $105 million.
- Insider Monkey•4 months ago
Do Hedge Funds Love Collegium Pharmaceutical Inc (COLL)?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of COLL earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Collegium Pharmaceutical Inc Earnings Call
- Simply Wall St.•4 months ago
How Financially Strong Is Collegium Pharmaceutical, Inc. (NASDAQ:COLL)?
While small-cap stocks, such as Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with its market cap of US$634m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...
- Insider Monkey•5 months ago
Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Are Hedge Funds Right About This Stock?
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
- Zacks•5 months ago
Collegium Pharmaceutical (COLL) Reports Q3 Loss, Lags Revenue Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -127.27% and -6.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 months ago
Collegium Pharmaceutical: 3Q Earnings Snapshot
The Canton, Massachusetts-based company said it had a loss of 50 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 25 cents per share. The results did not meet ...
- GlobeNewswire•5 months ago
Collegium Reports Third Quarter Financial Results
Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017Thirteen exclusive ER oxycodone formulary wins announced for.
- Benzinga•5 months ago
Collegium Pharmaceutical Q3 Earnings Preview
Don't be caught off-guard: Collegium Pharmaceutical, Inc. - Common Stock (NASDAQ: COLL ) releases its next round of earnings this Thursday, Nov. 8. View more earnings on COLL Want to skip the homework ...
- Zacks•6 months ago
Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
